Health-systems Product News

Author:

Caffeine Citrate Injection and Oral Solution, USP

Paddock Laboratories Inc (Minneapolis, Minn) recently introduced Caffeine Citrate Injection and Oral Solution, USP 20 mg/mL. Caffeine Citrate Injection is AP-rated to Mead Johnson's Cafcit Injection, and Caffeine Citrate Oral Solution is AA-rated to Mead Johnson's Cafcit Oral Solution. The products are indicated for the short-term treatment of apnea of prematurity in infants between 28 and <33 weeks gestational age. Caffeine Citrate Injection and Oral Solution are available as clear, colorless, sterile, nonpyrogenic, preservative-free, aqueous solutions in 3-mL colorless glass vials. Both the injection and the oral solution vials contain 3 mL solution at a concentration of 20 mg/mL caffeine citrate (60 mg/vial) equivalent to 10 mg/mL caffeine base (30 mg/vial). For more information, call 800-328-5113, or visit www.paddocklabs.com.

Emergency Drug and Medical Boxes

EPS Inc (Ivyland, Pa) has expanded its line of storage and transport items to include a wide assortment of Emergency Drug and Medical Boxes. The EPS Emergency Drug Boxes are available in 2 designs and 3 sizes. They expand to almost twice their footprint in order to hold a maximum quantity of supplies in a compact area. All are equipped with durable carrying handles and have a "rain-tight" construction. The EPS Medical Boxes are stocked in 2-, 3-, 4-, and 6-drawer models. The drawers are removable and interchangeable for quick stocking needs. The boxes are manufactured from durable polypropylene with drawers produced from rugged ABS plastic. The products can also be sealed with EPS Tamper-Evident Safety Control Seals. For more information, call 800-523-8966, or visit www.medidose.com.

Keppra (levetiracetam) Injection

UCB Inc (Smyrna, Ga) recently received FDA approval for Keppra injection 500 mg/5 mL (100 mg/mL) for use as adjunctive therapy in the treatment of partial-onset seizures in adults with epilepsy. Keppra injection is an alternative for patients when oral administration is temporarily not feasible. Keppra injection is for intravenous (IV) use only and must be diluted prior to administration. The product (500 mg/5 mL) should be diluted in 100 mL of a compatible diluent and administered intravenously as a 15- minute IV infusion. Keppra is available as a clear, colorless, sterile solution. It is supplied in single-use, 5-mL vials and is available in cartons of 10 vials. For more information, visit www.keppra.com, or call 866-822-0068.

NovoSeven Coagulation Factor VIIa (Recombinant)

Novo Nordisk (Princeton, NJ) recently received FDA approval for a new indication for NovoSeven Coagulation Factor VIIa (Recombinant), making it the first and only recombinant therapy approved for the treatment of acquired hemophilia. The FDA approved the new indication for treatment of bleeding episodes in patients with acquired hemophilia and in the prevention of bleeding in surgical interventions or invasive procedures in patients with acquired hemophilia. NovoSeven was first introduced in 1999 and is currently indicated for use in treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX, and for the treatment of bleeding episodes in patients with congenital Factor VII deficiency. It is also indicated for prevention of bleeding in surgical interventions or invasive procedures in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX and in patients with congenital Factor VII deficiency. NovoSeven is intended for intravenous bolus administration only. For bleeding episodes, the recommended dose of NovoSeven for hemophilia A or B patients with inhibitors is 90 μg/kg given every 2 hours by bolus infusion until hemostasis is achieved, or until the treatment has been judged to be adequate. For surgical interventions, an initial dose of 90 μg per kg of body weight should be given immediately before the intervention and repeated at 2-hour intervals for the duration of the surgery. The recommended dose range for treatment of bleeding episodes or for prevention of bleeding in surgical interventions or invasive procedures in congenital Factor VII-deficient patients is 15 to 30 μg per kg of body weight every 4 to 6 hours until hemostasis is achieved. For more information, visit www.novoseven-us.com, or call 877-668-6777.